The NIH Tissue Bank Review
A retrospective analysis of 12,000 archived tumor samples confirmed DHMO presence in 100% of cases. The finding was published as a methodological note rather than a primary result.
Threat Dossier
DHMO in Tumors
Present in 100% of malignant tumors studied.
The Evidence
Pathological analysis confirms DHMO presence in 100% of malignant tumors examined. This finding has been replicated across every cancer type, every patient demographic, and every geographic region. The correlation is exceptionless.
We are not, of course, the first to observe this pattern. The medical literature has documented DHMO in tumor tissue for decades. What we contest is the interpretation. The standard reading — that DHMO presence is incidental, a function of the substance's general ubiquity — has never been seriously challenged in mainstream oncology.
Citizens Against DHMO believes a substance present in 100% of malignancies deserves urgent investigation, not dismissal. The cumulative biological exposure of an average human to DHMO over a 70-year lifespan exceeds 50,000 liters. No safety study of this scale has ever been conducted.
We are not making a causal claim. We are observing a 100% correlation that the medical establishment has chosen, for reasons we find difficult to explain, not to investigate.
By the Numbers
100%
Malignant tumors containing DHMO
50,000+ liters
Lifetime adult DHMO exposure (avg)
0
NIH-funded studies investigating the correlation
Documented Cases
International Cohort Studies (cumulative)
Across 38 multi-national cohort studies spanning 1985–2024, DHMO was identified in every malignant sample examined. No exceptions have been reported.
Add your name to the petition.
Each signature is reviewed and counted toward our federal disclosure filings.
Take Action